FrancophonIA/ELRC3.0 huggingface dataset:
English: Silodyx 8 mg are white, opaque, hard gelatin capsules, size 0 (approximately 21.7 x 7.6 mm).
Estonian: Silodyx 8 mg on valged läbipaistmatud kõvad želatiinkapslid, suurusega 0 (ligikaudu 21,7 x 7,6 mm).
English: Silodyx 4 mg are yellow, opaque, hard gelatin capsules, size 3 (approximately 15.9 x 5.8 mm).
Estonian: Silodyx 4 mg on kollased läbipaistmatud kõvad želatiinkapslid, suurusega 3, (ligikaudu 15,9 x 5,8 mm).
English: Dizziness when standing up and occasionally fainting may occur when taking Silodyx, particularly when starting treatment or if you are taking other medicines that lower blood pressure.
Estonian: Silodyx'i võtmisel, eriti ravi alguses või siis, kui kasutate teisi vererõhku langetavaid ravimeid, võib püsti tõusmisel tekkida peapööritus või aeg-ajalt esineda minestamine.
English: Silodyx is selective for the receptors located in the prostate, bladder and urethra.
Estonian: Silodyx toimib selektiivselt eesnäärmes, põies ja kusitis paiknevatele retseptoritele.
English: How to take Silodyx
Estonian: Kuidas Silodyx'i võtta
English: It has been demonstrated in vitro that the α1A:α1B binding ratio of silodosin (162:1) is extremely high.
Estonian: In vitro uuringud on näidanud, et silodosiini α1A:α1B
English: Yellow, opaque, hard gelatin capsule, size 3 (approximately 15.9 x 5.8 mm).
Estonian: Kollane läbipaistmatu kõva želatiinkapsel, suurus 3 (ligikaudu 15,9 x 5,8 mm).
English: Urticaria1 Drug eruption1
Estonian: Nahalööve1, Sügelus1
English: White, opaque, hard gelatin capsule, size 0 (approximately 21.7 x 7.6 mm).
Estonian: Valge läbipaistmatu kõva želatiinkapsel, suurus 0 (ligikaudu 21,7 x 7,6 mm).
English: In patients with severe renal impairment administration of Silodyx is not recommended.
Estonian: Tõsise neerukahjustusega patsientidele ei soovitata Silodyx'i manustada.
English: Takeda Italia S.p.A. Tel: +39 06 502601
Estonian: Tel: + 39 06 502601
English: In a placebo-controlled study in 24 subjects 45-78 years of age receiving silodosin, the co-administration of sildenafil 100 mg or tadalafil 20 mg induced no clinically meaningful mean decreases in systolic or diastolic blood pressure, as assessed by orthostatic tests (standing versus supine).
Estonian: Silodosiini saava 24 patsiendiga (vanus 45...78 eluaastat) läbi viidud platseebokontrolliga uuringus ei põhjustanud 100 mg sildenafiili või 20 mg tadalafiili samaaegne manustamine kliinilist oluliselt süstoolse ega diastoolse vererõhu keskmist vähenemist.
English: The use of silodosin in patients with severe renal impairment (CLCR <30 ml/min) is not recommended (see sections 4.2 and 5.2).
Estonian: Tõsise neerukahjustusega (CLCR < 30 ml/min) patsientidel ei ole silodosiini kasutamine soovitatav (vt lõigud 4.2 ja 5.2).
English: For this purpose Silodyx 4 mg hard capsules are available.
Estonian: Selleks otstarbeks on saadaval Silodyx'i 4 mg kõvakapslid.
English: IPSS Irritative symptoms
Estonian: Ärritavad sümptomid IPSS-i järgi
English: • medicines which lower blood pressure (in particular, medicines called alpha1-blockers, such as prazosin or doxazosin) as there may be the potential risk that the effect of these medicines is increased whilst taking Silodyx.
Estonian: • vererõhku langetavaid ravimeid (iseäranis alfa1-blokaatoreid nagu prasosiin või doksasosiin),
English: How to store Silodyx
Estonian: Kuidas Silodyx'i säilitada
English: A starting dose of 4 mg once daily is recommended in patients with moderate renal impairment (CLCR ≥ 30 to < 50 mL/min), which may be increased to 8 mg once daily after one week of treatment, depending on the individual patient's response.
Estonian: Mõõduka neerukahjustusega (CLCR ≥ 30 kuni < 50 ml/min) patsientidel on soovitatavaks algannuseks 4 mg üks kord ööpäevas.
English: Silodyx 4 mg and 8 mg hard capsules
Estonian: Silodyx 4 mg ja 8 mg kõvakapslid
English: Silodyx 4 mg hard capsules Each hard capsule contains 4 mg silodosin.
Estonian: Silodyx 4 mg kõvakapslid Iga kõvakapsel sisaldab 4 mg silodosiini.
English: The recommended dose is one capsule of Silodyx 8 mg daily.
Estonian: Soovitatav annus on üks kapsel Silodyx 8 mg üks kord ööpäevas.
English: Silodyx 8 mg hard capsules Each hard capsule contains 8 mg silodosin.
Estonian: Silodyx 8 mg kõvakapslid Iga kõvakapsel sisaldab 8 mg silodosiini.
English: No. of patients
Estonian: Patsientide erirühmad
English: Protein binding of silodosin glucuronide is 91%.
Estonian: Silodosiinglükuroniid seondub plasmavalkudega 91 % ulatuses.
English: Talk to your doctor or pharmacist before taking Silodyx
Estonian: Enne Silodyx'i võtmist pidage nõu oma arsti või apteekriga.
English: Silodyx 4 mg hard capsules Silodyx 8 mg hard capsules
Estonian: Silodyx 4 mg kõvakapslid Silodyx 8 mg kõvakapslid
English: Zambon Nederland B.V. Tel: + 31 33 4504370
Estonian: Tel: + 31 33 4504370
English: There is no relevant use of Silodyx in the paediatric population for the indication of benign prostatic hyperplasia (BPH).
Estonian: Lapsed Puudub Silodyx'i asjakohane kasutus lastel healoomulise prostata hüperplaasia näidustusel.
English: Silodyx 8 mg hard capsules silodosin
Estonian: Silodyx 8 mg kõvakapslid silodosiin
English: Silodyx 4 mg hard capsules silodosin
Estonian: Silodyx 4 mg kõvakapslid silodosiin
English: Silodosin
Estonian: Neerukahjustus
English: It is important that you immediately inform your eye specialist if you are using or have previously used Silodyx.
Estonian: Kui te kasutate või olete eelnevalt kasutanud Silodyx'i on oluline silmaarsti sellest viivitamatult teavitada.
English: Each hard capsule contains 8 mg silodosin.
Estonian: Üks kõvakapsel sisaldab 8 mg silodosiini.
English: Each hard capsule contains 4 mg silodosin.
Estonian: Üks kõvakapsel sisaldab 4 mg silodosiini.
English: • Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with Silodyx.
Estonian: • Eesnäärme healoomulise suurenemise ja eesnäärmevähi korral võivad ilmneda ühesugused sümptomid.
English: EXPIRY DATE
Estonian: Patsien tide arv
English: Abnormal liver function tests1
Estonian: Maksafunkt siooni näitajate nor mist kõrvalekald ed1
English: Silodyx 4 mg hard capsules
Estonian: Silodyx 4 mg kõvakapslid
English: Silodyx 8 mg hard capsules
Estonian: Silodyx 8 mg kõvakapslid
English: 10 April 2013
Estonian: 10. aprill 2013
English: The European Commission issued a decision on 10 April 2013.
Estonian: Euroopa Komisjon tegi otsuse 10. aprillil 2013.
English: Outcome of a procedure under Article 13 of Regulation (EC) 1234/2008
Estonian: Määruse (EÜ) nr 1234/2008 artikli 13 kohase esildismenetluse tulemus
English: What is Kantos Master?
Estonian: Mis on Kantos Master?
English: In December 2011, the company applied for an additional use in Germany.
Estonian: 2011. aasta detsembris taotles ettevõte Saksamaal lisanäidustust.
English: The Committee looked at the study presented by the company to support its application.
Estonian: Inimravimite komitee vaatas üle uuringu, mille ettevõte oli esitanud oma taotluse toetuseks.
English: Why was Kantos Master reviewed?
Estonian: Miks Kantos Masteri taotlus uuesti läbi vaadati?
English: On 17 January 2013, the European Medicines Agency completed an arbitration procedure for Kantos Master and associated names.
Estonian: 17. jaanuaril 2013 viis Euroopa Ravimiamet lõpule Kantos Masteri ja sarnaste nimetuste vahekohtumenetluse.
English: Kantos Master is used as maintenance therapy in patients who have asthma.
Estonian: Kantos Masterit kasutatakse säilitusraviks astmaga patsientidel.
English: It is inhaled once or twice a day, in order to keep asthma under control and reduce symptoms.
Estonian: Seda inhaleeritakse astma kontrolli all hoidmiseks ja sümptomite leevendamiseks üks või kaks korda ööpäevas.
English: Kantos Master is authorised under a mutual recognition procedure based on an initial authorisation granted by Germany.
Estonian: Kantos Master on saanud müügiloa vastastikuse tunnustamise menetluse kaudu, mis toetub Saksamaa antud esialgsele müügiloale.
English: Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom (the ‘concerned Member States').
Estonian: Norra, Poola, Portugal, Rumeenia, Slovakkia, Sloveenia, Hispaania, Rootsi ja Ühendkuningriik (asjaomased liikmesriigid).
English: On 13 December 2012, Germany referred the matter to the CHMP for arbitration.
Estonian: Saksamaa suunas 13. detsembril 2012 küsimuse inimravimite komiteele vahekohtumenetluseks.
English: Kantos Master is marketed in all EU Member States except Czech Republic, Ireland, Malta Portugal and Slovakia under the names Kantos, Formodual, Foster, Inuxair, Innovair and associated names.
Estonian: Kantos Masterit turustatakse kõikides ELi liikmesriikides (välja arvatud Tšehhi Vabariigis, Iirimaal, Maltal, Portugalis ja Slovakkias) nimede Kantos, Formodual, Foster, Inuxair, Innovair ja sarnaste nimetuste all.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to arbitrate on a requested change to the marketing authorisation for these medicines to include a new use as rescue therapy for acute relief of asthma symptoms.
Estonian: Ravimiameti inimravimite komitee paluti vahekohtunikuks nende ravimite müügiloa muudatuse taotlemisel uue näidustuse lisamisega kasutamiseks leevendusravimina ägedate astmasümptomite leevendamiseks.
English: The grounds for the referral were the concerns of Sweden that the data on Kantos Master submitted in the application were not sufficient to demonstrate its effectiveness for MART.
Estonian: Esildise aluseks oli Rootsi tõstatatud probleem seoses sellega, et taotluses esitatud andmed Kantos Masteri kohta ei olnud piisavad efektiivsuse näitamiseks MART-raviskeemi jaoks.
English: However, the Member States were unable to reach agreement on whether to accept this indication for Kantos Master.
Estonian: Liikmesriigid ei jõudnud kokkuleppele selle näidustuse heakskiitmise osas Kantos Masteri jaoks.
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP agreed that Kantos Master has been shown to reduce the risk of severe exacerbation of asthma and prolong the time between exacerbations when part of the dose is given on an as-needed basis as MART.
Estonian: Tuginedes olemasolevate andmete hindamisele ja komiteesisesele teaduslikule arutelule, nõustus inimravimite komitee, et andmete alusel vähendab Kantos Master astma raskete ägenemisjuhtude riski ning pikendab aega haigusnähtude süvenemise vahel, kui osa annusest manustatakse vajaduse korral MART-raviskeemi alusel.
English: The CHMP noted that MART was not compared with the standard of care according to current guidelines, but agreed that there was no evidence that patients in the comparison group had been undertreated, as patients in both groups had shown clinical benefit from their maintenance treatment.
Estonian: Inimravimite komitee märkis, et MART-raviskeemi ei võrreldud kehtivate juhiste kohase standardraviga, kuid otsustas, et võrdlusrühma patsiente ei saanud pidada alaravituteks, sest mõlema uuringurühma patsientidel täheldati säilitusravi kliinilist kasulikkust.
English: The CHMP therefore concluded that the benefits of Kantos Master for MART outweigh its risks and recommended that the marketing authorisation be granted in Germany and the concerned Member States.
Estonian: Inimravimite komitee otsustas, et Kantos Masteri kasulikkus MART-raviskeemis on suurem kui sellega kaasnevad riskid, ja soovitas anda Saksamaal ning asjaomastes liikmesriikides ravimi müügiloa.
English: Questions and answers on Kantos Master and associated names (beclomethasone dipropionate / formoterol fumarate, inhaler) EMA/21628/2013 rev.1
Estonian: Teave Kantos Masteri ja sarnaste nimetuste (beklometasoondipropionaat/formoteroolfumaraat, inhalaator) kohta EMA/21628/2013 rev.1
English: The company that makes the medicine is Chiesi.
Estonian: Ravimit toodab ettevõte Chiesi.
English: Kantos Master is a medicine that contains two active substances: beclomethasone dipropionate, a corticosteroid (a medicine that reduces inflammation), and formoterol fumarate, a bronchodilator (a medicine that opens the airways, allowing easier breathing) with a long duration of action.
Estonian: Kantos Master sisaldab kahte toimeainet: beklometasoondipropionaati, mis on kortikosteroid (põletikku vähendav ravim), ja formoteroolfumaraati, mis on pika toimeajaga bronhodilataator (hingamisteid avav ravim, mis muudab hingamise kergemaks).
English: The application was for the use of Kantos Master for both maintenance therapy of asthma and for relief of symptoms when they arise instead of the use of a separate short-acting bronchodilator (maintenance and reliever therapy, or MART).
Estonian: Taotlus puudutas Kantos Masteri kasutamist nii säilitusraviks astmaga patsientidel kui ka sümptomite leevendamiseks nende tekkimisel eraldi lühitoimelise bronhodilataatori kasutamise asemel (säilitus- ja leevendusravi ehk MART-raviskeem).
English: The company wanted the authorisation to be recognised in the following Member States: Austria, Belgium, Bulgaria, Cyprus, Denmark, Estonia, Finland, France, Greece, Hungary, Italy, Latvia, Lithuania,
Estonian: Ettevõte soovis müügiloa tunnustamist järgmistes liikmesriikides: Austria, Belgia, Bulgaaria, Küpros, Taani, Eesti, Soome, Prantsusmaa, Kreeka, Ungari, Itaalia, Läti, Leedu, Luksemburg, Madalmaad,
English: It also took note of relevant literature supporting the principle of using such a combination of corticosteroid and long-acting bronchodilator (beclometasone and formoterol) for MART.
Estonian: Komitee arvestas ka asjakohast kirjandust, mis toetas kortikosteroidi ja pika toimeajaga bronhodilataatori (beklometasooni ja formoterooli) kasutamise põhimõtet MART-raviskeemis.
English: The Committee concluded that the benefits of Kantos Master outweigh its risks in the new use and the change to the marketing authorisation can be granted in Germany and the following Member States: Austria, Belgium, Bulgaria, Cyprus, Denmark, Estonia, Finland, France, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Romania, Slovenia, Spain, Sweden and the United Kingdom.
Estonian: Inimravimite komitee otsustas, et Kantos Masteri kasulikkus on uue näidustuse puhul suurem kui sellega kaasnevad riskid, ja soovitas muuta ravimi müügiloa Saksamaal ning järgmistes liikmesriikides: Austria, Belgia, Bulgaaria, Küpros, Taani, Eesti, Soome, Prantsusmaa, Kreeka, Ungari, Itaalia, Läti, Leedu, Luksemburg, Madalmaad, Norra, Poola, Rumeenia, Sloveenia, Hispaania, Rootsi ja Ühendkuningriik.
English: If patients develop symptoms of asthma (wheezing and difficulty breathing) inhalation of a separate bronchodilator medicine with a rapid onset and short duration of action is advised for relief (rescue therapy).
Estonian: Kui patsientidel tekivad astmasümptomid (vilistav hingamine ja hingamisraskused), soovitatakse leevenduseks inhaleerida kiire toime ja lühikese toimeajaga bronhodilataatorit (leevendusravi).
English: Questions and answers on Kantos Master and associated names (beclomethasone dipropionate / formoterol fumarate, inhaler)
Estonian: Teave Kantos Masteri ja sarnaste nimetuste (beklometasoondipropionaat/formoteroolfumaraat, inhalaator) kohta
English: In particular, in the main study comparing the use of Kantos Master for MART versus maintenance treatment with Kantos Master plus a short-acting bronchodilator given for relief, there were concerns that the comparison group might not have been receiving adequate maintenance treatment, which could have made the results in the MART group look better than they really were.
Estonian: Konkreetselt tekkisid probleemid seoses põhiuuringuga, mis võrdles Kantos Masteri kasutamist MART-raviskeemis ja Kantos Masteriga teostatavat säilitusravi koos leevenduseks manustatava lühitoimelise bronhodilataatoriga.
English: What measures are being taken to ensure the safe and effective use of Vidaza?
Estonian: Mis meetmed võetakse, et tagada Vidaza ohutu ja efektiivne kasutamine?
English: Treatment continues for at least six cycles and then for as long as it benefits the patient.
Estonian: Ravi kestab vähemalt kuus tsüklit ja seejärel nii kaua, kuni see on patsiendile kasulik.
English: The effect of Vidaza was similar in all three diseases.
Estonian: Vidaza toime oli sarnane kõigi kolme haiguse korral.
English: Vidaza has been studied in two main studies.
Estonian: Vidazat uuriti kahes põhiuuringus.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vidaza on 17 December 2008.
Estonian: Euroopa Komisjon andis Vidaza müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. detsembril
English: This four-week period is one ‘cycle'.
Estonian: Seda neljanädalast perioodi nimetatakse üheks ravitsükliks.
English: The full EPAR for Vidaza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Vidaza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Vidaza azacitidine
Estonian: Vidaza asatsitidiin
English: Other information about Vidaza
Estonian: Muu teave Vidaza kohta
English: Both studies compared Vidaza with conventional care (treatment chosen for each patient based on local practice and the patient's condition).
Estonian: Mõlemas uuringus võrreldi Vidazat tavapärase raviga (iga patsiendi jaoks kohaliku praktika ja patsiendi seisundi järgi valitud ravi).
English: Azacitidine is an analogue of cytidine, which means that it is incorporated into the genetic material of cells (RNA and DNA).
Estonian: Asatsitidiin on tsütidiini analoog, mis tähendab, et see kaastakse rakkude geenimaterjali (RNA ja DNA).
English: The main measure of effectiveness was how long the patients survived.
Estonian: Efektiivsuse põhinäitaja oli patsientide elumus.
English: The recommended dose of Vidaza is 75 mg per square metre body surface area (calculated using the patient's height and weight).
Estonian: Vidaza soovitatav annus on 75 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi pikkuse ja kehamassi järgi).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vidaza have been included in the summary of product characteristics and the package leaflet.
Estonian: Vidaza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: If the blood counts fall too low or if the patient develops kidney problems, the next treatment cycle should be delayed or a lower dose should be used.
Estonian: Kui vererakkude sisaldus on liiga väike või kui patsiendil tekivad neeruprobleemid, tuleb järgmise ravitsükli algus edasi lükata või kasutada väiksemat annust.
English: The CHMP decided that Vidaza's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Vidaza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The most common side effects of Vidaza in more than 60% of patients with myelodysplastic syndromes, CMML or AML (20 to 30% abnormal cells) are blood reactions including thrombocytopenia (low platelet counts), neutropenia (low levels of neutrophils, a type of white blood cell) and leucopenia (low white blood cell counts), side effects affecting the stomach and gut including nausea and vomiting, and injection site reactions.
Estonian: Vidaza kõige sagedamad kõrvalnähud enam kui 60%-l patsientidest, kellel oli müelodüsplastilised sündroomid, müelomonotsütaanse leukeemia või äge müeloidleukeemia (ebanormaalseid rakke 2030%), on verereaktsioonid, sh trombotsütopeenia (vereliistakute väike sisaldus), neutropeenia (teatud leukotsüütide neutrofiilide väike sisaldus) ja leukopeenia (leukotsüütide väike sisaldus), mao ja soolestikuga seotud kõrvalnähud, sealhulgas iiveldus ja oksendamine, ning süstekoha reaktsioonid.
English: For more information about treatment with Vidaza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Vidazaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The summaries of the opinion of the Committee for Orphan Medicinal Products for Vidaza can be found on the Agency's website: here (myelodysplastic syndromes) and here (AML).
Estonian: Harvikravimite komitee arvamuse kokkuvõte Vidaza kohta on ameti veebilehel: siin (müelodüsplastilised sündroomid) ja siin (äge müeloidleukeemia).
English: Because the number of patients with these diseases is low, the diseases are considered ‘rare', and Vidaza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 6 February 2002 for myelodysplastic syndromes and on 29 November 2007 for AML.
Estonian: Et nende haigustega patsientide arv on väike ja need haigused esinevad harva, nimetati Vidaza 6. veebruaril 2002 müelodüsplastiliste sündroomide ja 29. novembril 2007 ägeda müeloidleukeemia harvikravimiks.
English: What is the risk associated with Vidaza?
Estonian: Mis riskid Vidazaga kaasnevad?
English: Vidaza was more effective than conventional care in extending survival.
Estonian: Vidaza oli elumuse pikendamisel efektiivsem kui tavapärane ravi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vidaza.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Why has Vidaza been approved?
Estonian: Miks Vidaza heaks kiideti?
English: Vidaza treatment should be started and monitored under the supervision of a doctor experienced in the use of cancer medicines.
Estonian: Ravi Vidazaga peab toimuma vähiravimite kasutamises kogenud arsti järelevalve all.
English: This is a summary of the European public assessment report (EPAR) for Vidaza.
Estonian: See on ravimi Vidaza Euroopa avaliku hindamisaruande kokkuvõte.
English: Vidaza is used when the bone marrow consists of 10 to 29% abnormal cells and the bone marrow is not producing large numbers of white blood cells;
Estonian: Vidazat kasutatakse, kui luuüdi sisaldab 10-29% ebanormaalseid rakke ja selles ei teki rohkesti leukotsüüte;
English: Vidaza is a medicine that contains the active substance azacitidine.
Estonian: Vidaza on ravim, mis sisaldab toimeainena asatsitidiini.
English: It is given as an injection under the skin of the upper arm, thigh or abdomen (tummy) every day for one week, followed by three weeks with no treatment.
Estonian: Ravimit manustatakse nahaaluse süstena õlavarde, reide või kõhupiirkonda iga päev ühe nädala jooksul, millele järgneb kolmenädalane ravipaus.
English: The active substance in Vidaza, azacitidine, belongs to the group ‘anti-metabolites'.
Estonian: Vidaza toimeaine asatsitidiin kuulub antimetaboliitide rühma.
English: In the second study in AML patients with more than 30% abnormal cells, patients receiving Vidaza survived for an average of 10.4 months, compared with 6.5 months in patients receiving conventional care.
Estonian: Teises uuringus ägeda müeloidleukeemiaga patsientidel, kellel oli enam kui 30% ebanormaalseid rakke, oli keskmine elumus Vidazat kasutanud patsientidel 10,4 kuud ja tavapärast ravi saanud patsientidel 6,5 kuud.
English: These actions are thought to correct the problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders, and to kill cancerous cells in leukaemia.
Estonian: Arvatakse, et need toimed korrigeerivad luuüdis olevate ebaküpsete vererakkude küpsemis- ja kasvuprobleeme, mis põhjustavad müelodüsplastilisi häireid, ja hävitavad leukeemia korral kasvajarakke.